These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18971421)

  • 21. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.
    Lutzky VP; Crooks P; Morrison L; Stevens N; Davis JE; Corban M; Hall D; Panizza B; Coman WB; Coman S; Moss DJ
    Clin Vaccine Immunol; 2014 Feb; 21(2):256-9. PubMed ID: 24351754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
    Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
    Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
    Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
    Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy.
    Faè DA; Martorelli D; Mastorci K; Muraro E; Dal Col J; Franchin G; Barzan L; Comaro E; Vaccher E; Rosato A; Dolcetti R
    Cancer Immunol Res; 2016 May; 4(5):431-40. PubMed ID: 27009165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for Epstein-Barr virus-associated tumors.
    Comito MA; Sun Q; Lucas KG
    Leuk Lymphoma; 2004 Oct; 45(10):1981-7. PubMed ID: 15370241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.
    Kuzushima K; Yamamoto M; Kimura H; Ando Y; Kudo T; Tsuge I; Morishima T
    Clin Exp Immunol; 1996 Feb; 103(2):192-8. PubMed ID: 8565299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
    Savoldo B; Huls MH; Liu Z; Okamura T; Volk HD; Reinke P; Sabat R; Babel N; Jones JF; Webster-Cyriaque J; Gee AP; Brenner MK; Heslop HE; Rooney CM
    Blood; 2002 Dec; 100(12):4059-66. PubMed ID: 12393655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for EBV-associated malignancies.
    Merlo A; Turrini R; Dolcetti R; Zanovello P; Rosato A
    Int J Hematol; 2011 Mar; 93(3):281-293. PubMed ID: 21336546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma.
    DiMaio JM; Van Trigt P; Gaynor JW; Davis RD; Coveney E; Clary BM; Lyerly HK
    Circulation; 1995 Nov; 92(9 Suppl):II202-5. PubMed ID: 7586409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas.
    Cho HI; Hong YS; Lee MA; Kim EK; Yoon SH; Kim CC; Kim TG
    Int J Hematol; 2006 Jan; 83(1):66-73. PubMed ID: 16443556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.
    Khanna R; Busson P; Burrows SR; Raffoux C; Moss DJ; Nicholls JM; Cooper L
    Cancer Res; 1998 Jan; 58(2):310-4. PubMed ID: 9443410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma.
    Wang G; Mudgal P; Wang L; Shuen TWH; Wu H; Alexander PB; Wang WW; Wan Y; Toh HC; Wang XF; Li QJ
    Oncoimmunology; 2021; 10(1):1955545. PubMed ID: 34377592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.